Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancies and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD72 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD72 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD72 Products |
| Gene Delivery | CD72 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD72 Products |
| Benchmark Ab | Anti-CD72 (Sequence of Clinical/Preclinical Leads) Recombinant positive control. |
View CD72 Products |
| Validator | CD72 siRNA Set For knockdown verification. |
View CD72 Products |
| Related Target A | SEMA4D CD72 ligand (also known as CD100); critical for CD72-mediated immune regulation and receptor blocking assays. |
View SEMA4D Products |
| Related Target B | CD22 B-cell co-receptor; key target for combination therapies and bispecific CAR-T/ADC development in B-cell malignancies. |
View CD22 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation of Type II Membrane Protein | HEK293 mammalian expression system guarantees native glycosylation and correct disulfide-linked homodimerization. |
| CD72-SEMA4D Interaction Blocking | High-purity human and cynomolgus SEMA4D and CD72 ortholog proteins available with strictly verified sequence integrity. |
| Lack of Controls | Preclinical benchmark antibodies (recombinant biosimilars) included to validate binding assays. |
| False Positives | Sequence-verified CD72 siRNA included for specific target knockdown validation in cell-based assays. |
Live CD72 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
"The race for CD72 therapeutics is intensifying, with major players shifting focus from traditional mAbs to CAR-T therapies and ADCs. As first-generation CD19-targeted therapies face antigen-loss resistance in B-cell malignancies, the next wave of R&D is targeting CD72 as a highly viable salvage and combination target."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T (including Bispecific) | Academic Institutes, Biotech Startups | Refractory B-ALL, DLBCL | Stable cell line construction (Need high-titer CD72 Lentivirus) |
| Antibody-Drug Conjugates (ADC) | Biopharma Innovators | B-Cell Lymphomas | Internalization Assay (Need high-purity, native-conformation ECD-Fc) |
| Agonistic Monoclonal Antibodies | Autoimmune-focused Biopharma | Systemic Lupus Erythematosus (SLE) | Receptor Activation & CD100 Blocking Assay (Need CD72/SEMA4D proteins) |